BioSpace News Archive

Medicenna Therapeutics Corp., a clinical-stage immunotherapy company focused on the development of Superkines, announced that its shares will commence trading on the OTCQB Venture Market in the United States, effective December 19, 2023.

Atavistik Bio Raises Additional $40 Million to Advance Precision Allosteric Small Molecule Therapeutics.

Tiziana Life Sciences Ltd. today announced “first patient dosed” in its Phase 2a study comparing two doses of intranasal foralumab and placebo in patients with non-active secondary-progressive multiple sclerosis (na-SPMS).

LTS, a leading pharmaceutical technology company, announced that it has received a grant from the Bill & Melinda Gates Foundation.

enGene Holdings Inc. today announced the appointment of Lota S. Zoth, CPA, as a member of the Board of Directors and Audit Committee Chair.

HuidaGene Therapeutics (辉大基因"HuidaGene”) today announced the U.S. FDA granted Rare Pediatric Drug Designation (RPDD) to HG302, a novel CRISPR-Cas12 DNA-editing therapy, to treat Duchenne muscular dystrophy (DMD), affecting 1 in ~5,000 newborn boys.

Element Biosciences, Inc. today announced that Element CEO and Co-Founder Molly He will be presenting a corporate update at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco.

Ayana Bio is pleased to announce the appointment of Jim Hamilton, former President of DSM Nutritional Products USA and CEO of OmniActive Health Technologies, to the company’s board of directors.

FGen AG, a subsidiary of Ginkgo Bioworks, based in Switzerland, has been awarded funding through the European Innovation Council’s Pathfinder Challenge program.

Gilead Sciences, Inc. (Nasdaq: GILD) today announced an agreement with Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, headquartered in Holon, Israel, to exclusively license its potential first-in-class, pre-clinical antibody program against IL-18 binding protein, including the COM503 drug candidate.